2020
DOI: 10.1039/c9cc07807j
|View full text |Cite
|
Sign up to set email alerts
|

Nucleoside-modified AdoMet analogues for differential methyltransferase targeting

Abstract: Methyltransferases modify a wide range of biomolecules using S-adenosyl-l-methionine (AdoMet) as cosubstrate. Enzymatic generation of nucleoside-modified AdoMet analogues and conversion by different methyltransferases is shown.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
35
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
6

Relationship

4
2

Authors

Journals

citations
Cited by 27 publications
(36 citation statements)
references
References 41 publications
0
35
0
1
Order By: Relevance
“…[20] Efforts to circumvent the stability issues and the need to prepare SAM analogues separately have focused on developing tandem enzymatic reactions, where the cofactor is synthesized in situ, followed by MTase-mediated methylation. [21][22][23][24][25][26][27] Another alternative is to develop shelf-stable SAM analogues (e. g., 7-9), which are accepted by MTases as substrates but could also be stored prior to use ( Figure 2B). [20] The second challenge in establishing a biocatalytic methylation platform arises from the inherent need to use stoichiometric amounts of the cofactor (or analogue), which invariably produces an equal amount of the S-adenosylhomocysteine (SAH) by-product.…”
Section: Current Challenges Of Biocatalytic Alkylationmentioning
confidence: 99%
See 4 more Smart Citations
“…[20] Efforts to circumvent the stability issues and the need to prepare SAM analogues separately have focused on developing tandem enzymatic reactions, where the cofactor is synthesized in situ, followed by MTase-mediated methylation. [21][22][23][24][25][26][27] Another alternative is to develop shelf-stable SAM analogues (e. g., 7-9), which are accepted by MTases as substrates but could also be stored prior to use ( Figure 2B). [20] The second challenge in establishing a biocatalytic methylation platform arises from the inherent need to use stoichiometric amounts of the cofactor (or analogue), which invariably produces an equal amount of the S-adenosylhomocysteine (SAH) by-product.…”
Section: Current Challenges Of Biocatalytic Alkylationmentioning
confidence: 99%
“…[35] 4. Tandem enzymatic alkylation by using A) MAT, [9,[20][21]25,[37][38][39] B) an HMT-mediated SAM regeneration process, [40] and C) SalL to generate SAM analogues in situ.…”
Section: Development Of Sam Cofactor Regeneration Systemsmentioning
confidence: 99%
See 3 more Smart Citations